Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma ...
COSTA MESA, CA--(Marketwired - Mar 20, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol- …